Eli Lilly's Alzheimer's Drug to Be Reassessed by England's Health Regulator

England's drug price regulator is set to reevaluate its decision to exclude Eli Lilly's Alzheimer's medication from the National Health Service (NHS). Bloomberg posted on X that this development follows a successful appeal by the U.S. pharmaceutical company. The initial ruling had prevented the use of the drug within the state-run healthcare system, but the appeal has prompted a reassessment of its potential inclusion. The outcome of this review could impact the availability of the treatment for Alzheimer's patients in England.